Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05122559 (ClinicalTrials.gov)	November 2021	8/11/2021	Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis	Randomized Controlled Trial of N-acetyl Cysteine as a Neuroprotective Agent in Progressive Multiple Sclerosis	Multiple Sclerosis;Multiple Sclerosis, Primary Progressive;Multiple Sclerosis, Secondary Progressive	Drug: N-acetyl cysteine;Drug: Placebo	Emmanuelle Waubant	United States Department of Defense	Not yet recruiting	40 Years	70 Years	All	98	Phase 2	NULL
2	NCT03032601 (ClinicalTrials.gov)	January 5, 2017	19/1/2017	Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis	Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis	Multiple Sclerosis	Dietary Supplement: N-acetyl Cysteine	Thomas Jefferson University	NULL	Enrolling by invitation	21 Years	80 Years	All	55	N/A	United States
3	NCT02804594 (ClinicalTrials.gov)	October 1, 2016	3/6/2016	A Study of Oxidative Pathways in MS Fatigue	A Phase 2 Randomized, Placebo- Controlled, Parallel Group, Double Blinded Single Center Study on Effect of N-acetyl Cysteine Compared to Placebo on Fatigue in Patients With Progressive Multiple Sclerosis	Progressive Multiple Sclerosis;Fatigue	Drug: N-acetyl cysteine;Drug: Placebo	University of California, San Francisco	NULL	Completed	18 Years	75 Years	All	15	Phase 2	United States
4	EUCTR2008-000955-90-IT (EUCTR)	24/04/2007	12/03/2008	Randomized, single-blind, clinical and MRI study for evaluation of safety and efficacy of N-Acetyl Cysteine (NAC) associated with high-dose beta-Interferon in Relapsing-Remitting (RR) multiple sclerosis patients - renac	Randomized, single-blind, clinical and MRI study for evaluation of safety and efficacy of N-Acetyl Cysteine (NAC) associated with high-dose beta-Interferon in Relapsing-Remitting (RR) multiple sclerosis patients - renac	multiple sclerosis MedDRA version: 9.1;Level: HLT;Classification code 10052785;Term: Multiple sclerosis acute and progressive	Product Name: n-acetylcysteine INN or Proposed INN: Acetylcysteine	ISTITUTO C. MONDINO	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy